Literature DB >> 15660511

Therapeutic intervention and targets for sepsis.

Todd W Rice1, Gordon R Bernard.   

Abstract

Sepsis syndrome, a systemic response to infection, can beget devastating outcomes even in previously normal individuals. Recent research in septic patients has led to the discovery that early goal-directed resuscitation guided by continuous monitoring of mixed venous hemoglobin saturation, along with moderate doses of corticosteroids, can reduce mortality. An improved understanding of the complex interaction between the inflammatory and coagulant systems in sepsis pathophysiology has resulted in novel treatments, such as recombinant human activated protein C, which improves survival in patients with severe sepsis and a high risk of death. However, despite an increased understanding of the complex pathophysiology of this syndrome and the discovery of new, effective treatments, severe sepsis still results in significant morbidity and mortality. Consequently, investigations continue into additional therapeutic agents directed against novel targets. Following a review of recent advances in sepsis treatment, we briefly discuss a few of the new, promising therapeutic strategies currently being investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660511     DOI: 10.1146/annurev.med.56.082103.104356

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  45 in total

1.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  The effect of sRAGE-Fc fusion protein attenuates inflammation and decreases mortality in a murine cecal ligation and puncture model.

Authors:  Su Jin Jeong; Beom Jin Lim; Sungha Park; Donghoon Choi; Hye Won Kim; Nam Su Ku; Sang Hoon Han; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Inflamm Res       Date:  2012-07-10       Impact factor: 4.575

3.  Alpinia katsumadai H(AYATA) seed extract inhibit LPS-induced inflammation by induction of heme oxygenase-1 in RAW264.7 cells.

Authors:  Mee-Young Lee; Chang-Seob Seo; Jin-Ah Lee; In-Sik Shin; Su-Jeong Kim; HeyKyung Ha; Hyeun-Kyoo Shin
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

4.  Modulation of innate immune responses with synthetic lipid A derivatives.

Authors:  Yanghui Zhang; Jidnyasa Gaekwad; Margreet A Wolfert; Geert-Jan Boons
Journal:  J Am Chem Soc       Date:  2007-03-29       Impact factor: 15.419

5.  Has the rate of in-hospital infections after total joint arthroplasty decreased?

Authors:  Mohammad R Rasouli; Mitchell Gil Maltenfort; James J Purtill; William J Hozack; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

Review 6.  A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.

Authors:  Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2018-02-02       Impact factor: 4.962

7.  A simple mathematical model of signaling resulting from the binding of lipopolysaccharide with Toll-like receptor 4 demonstrates inherent preconditioning behavior.

Authors:  Beatrice Rivière; Yekaterina Epshteyn; David Swigon; Yoram Vodovotz
Journal:  Math Biosci       Date:  2008-10-11       Impact factor: 2.144

Review 8.  Advances in understanding sepsis.

Authors:  M Shimaoka; E J Park
Journal:  Eur J Anaesthesiol Suppl       Date:  2008

9.  Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome.

Authors:  Kyong-Su Park; Kyoung-Ho Choi; You-Sun Kim; Bok Sil Hong; Oh Youn Kim; Ji Hyun Kim; Chang Min Yoon; Gou-Young Koh; Yoon-Keun Kim; Yong Song Gho
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

10.  Regulatory mechanisms underlying sepsis progression in patients with tumor necrosis factor-α genetic variations.

Authors:  Yangzhou Liu; Ning Han; Qinchuan Li; Zengchun Li
Journal:  Exp Ther Med       Date:  2016-05-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.